Canada Breast Cancer Diagnostics Market By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Others), By Product (Platform-based Products, Instrument-based Products), By Application (Screening, Diagnostic & Predictive, Prognostic, Research), By End Use (Hospitals & Clinics, Diagnostic Centers and Medical Laboratories, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCanada Breast Cancer Diagnostics Market By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Others), By Product (Platform-based Products, Instrument-based Products), By Application (Screening, Diagnostic & Predictive, Prognostic, Research), By End Use (Hospitals & Clinics, Diagnostic Centers and Medical Laboratories, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
The Canada breast cancer diagnostics market is expected to experience significant growth over the forecast period. This can be attributed to the increasing prevalence of breast cancer and advancements in imaging technology, such as 3-D mammography, which are improving early detection and screening capabilities. Additionally, there is a growing demand for various diagnostic tests, including mammograms, breast magnetic resonance imaging, and biopsies, driven by the availability of highly effective medications. The demand for advanced mammography devices is also expected to contribute to the lucrative growth of the Canadian breast cancer diagnostics market. However, the presence of key market players expanding their operations in the country may limit market growth. For example, in 2020, approximately 27,400 women in Canada were diagnosed with breast cancer.
Increasing Breast Cancer Incidences
The increasing incidence of breast cancer in Canada has a significant impact on the growth of the Canada Breast Cancer Diagnostics Market. The growing number of breast cancer cases translates into a larger patient population requiring treatment. This expanded patient base creates a higher demand for breast cancer therapeutics, including surgery, radiation therapy, chemotherapy, targeted therapies, and hormonal therapies. The rising incidence of breast cancer contributes to the expansion of the market size and generates increased revenue opportunities for pharmaceutical companies, healthcare providers, and other stakeholders involved in breast cancer therapeutics. The market growth is driven by the need to cater to the growing patient population and provide effective treatment options. The increasing breast cancer incidence motivates greater investments in research and development (R&D) efforts focused on understanding the disease, discovering new treatment modalities, and improving existing therapies. Pharmaceutical companies, academic institutions, and government organizations allocate resources to develop innovative therapeutics to meet the growing demand for effective treatments. The rise in breast cancer incidence has led to a deeper understanding of the molecular and genetic basis of the disease. This knowledge has facilitated the development of targeted therapies that specifically act on cancer cells, reducing off-target effects and improving treatment outcomes. The demand for targeted therapies increases as the incidence of breast cancer rises, driving research and innovation in this area. The increasing incidence of breast cancer necessitates the conduct of more clinical trials to evaluate the safety and efficacy of novel therapeutics. These trials generate valuable data that contribute to the evidence base supporting the use of specific treatment options. The availability of robust clinical trial data is crucial in gaining regulatory approvals and facilitating the adoption of new therapeutics in clinical practice.
Growing Technological Advancements
In 2022, Abemaciclib (Verzenios) was approved by the National Institute for Health and Care Excellence (NICE) to treat some people with breast cancer that has a high-risk of returning. The new drug combination will be found at to adults with hormone receptor-positive, HER-2 negative, node positive breast cancer, on the NHS in England.
Research and Development
In 2023, January clinical trials of Phase 1b/2, an Open-Label Umbrella Study to evaluate the safety and efficacy of Elacestrant in Various Combination In Patients With Metastatic Breast Cancer have started.
Growing Demand for Personalized Medicine
The growing demand for personalized medicine has a significant influence on the growth of the Canada Breast Cancer Diagnostics Market. Recent developments in personalized medicine aim to provide tailored treatment approaches based on an individual's unique characteristics, including genetic makeup, tumor biology, and other relevant factors. In the context of breast cancer, personalized medicine allows healthcare providers to select treatment options that are more likely to be effective for specific patient subgroups. This demand for personalized treatment drives the development and availability of a wide range of targeted therapies, biomarker-driven therapies, and other personalized medicine interventions. Personalized medicine in breast cancer diagnostics enhances treatment efficacy. By understanding the specific genetic alterations and molecular signatures of a patient's tumor, healthcare providers can select therapies that target these specific abnormalities. This approach improves treatment response rates, reduces treatment resistance, and enhances overall treatment outcomes. The demand for personalized medicine is fueled by the desire for more effective treatments and improved patient outcomes. Personalized medicine approaches in breast cancer treatment help minimize adverse effects by tailoring therapies to individual patients. By considering a patient's genetic profile, biomarker status, and other factors, healthcare providers can identify treatments that are more likely to be well-tolerated and have fewer side effects. This reduction in treatment-related adverse effects leads to improved patient quality of life and satisfaction. Personalized medicine relies on the identification of biomarkers associated with specific tumor characteristics or treatment responses. The growing demand for personalized medicine has spurred research efforts to identify relevant biomarkers in breast cancer. These biomarkers can be used in the development of companion diagnostics, which aid in the selection of appropriate therapies for individual patients. The availability of companion diagnostics enhances treatment decision-making and contributes to market growth. The increasing demand for personalized medicine is closely tied to advancements in genomic sequencing technologies. Next-generation sequencing and other genomic profiling techniques enable comprehensive analysis of a patient's tumor, identifying genetic alterations, mutations, and molecular subtypes. These advancements in genomic sequencing technologies have expanded the scope of personalized medicine in breast cancer treatment and have driven the development of targeted therapies and precision medicine approaches.
Growing Collaboration and Partnerships
Collaboration and partnerships play a vital role in influencing the growth of the Canada Breast Cancer Diagnostics Market. Collaboration among researchers, pharmaceutical companies, academic institutions, and healthcare organizations fosters knowledge sharing, resource pooling, and expertise exchange. These collaborative efforts accelerate the pace of R&D activities, leading to advancements in understanding breast cancer biology, the discovery of new therapeutic targets, and the development of innovative treatment approaches. Collaborative R&D initiatives drive innovation, fuel market growth, and contribute to the expansion of treatment options. Collaborative partnerships enable the sharing of resources, infrastructure, and expertise among different stakeholders in the Canada Breast Cancer Diagnostics Market. Pharmaceutical companies often collaborate with academic institutions and research organizations to access specialized expertise, patient cohorts, and facilities for conducting clinical trials and preclinical studies. Such collaborations optimize resource utilization, enhance research capabilities, and expedite the development and commercialization of new therapies. Collaboration among multiple healthcare institutions and research centers enables the recruitment of larger patient cohorts for clinical trials. Collaborative clinical trials generate robust data sets that provide valuable insights into the safety and efficacy of new therapies. Additionally, collaborations promote data sharing among researchers and clinicians, leading to a more comprehensive understanding of treatment outcomes, disease progression, and patient response. The availability of shared clinical trial data supports evidence-based treatment decisions and contributes to market growth. Collaborative partnerships facilitate technology transfer and the commercialization of innovative technologies and therapies. Academic-industry collaborations, for example, allow academic institutions to transfer their research findings and intellectual property to pharmaceutical companies for further development and commercialization. These partnerships expedite the translation of scientific discoveries into clinical applications, leading to the availability of novel therapies in the market. Partnerships can be formed to ensure the availability and affordability of therapies to a larger patient population. Collaborations with healthcare systems, hospitals, and clinics help ensure the seamless integration of new treatments into clinical practice and enhance patient access to innovative therapies.
Government Initiatives and Support
Government initiatives and support play a crucial role in influencing the growth of the Canada Breast Cancer Diagnostics Market. Governments provide significant funding for breast cancer research and development, which fuels innovation in therapeutics. Funding is often allocated to research institutions, academic centers, and pharmaceutical companies to support studies focused on understanding breast cancer biology, discovering new treatment targets, and developing novel therapies. This financial support drives R&D activities, accelerates the development of effective treatments, and contributes to the growth of the market. Government regulatory bodies, such as Health Canada, play a critical role in ensuring the safety and efficacy of breast cancer therapeutics. These agencies provide support and guidance to pharmaceutical companies during the drug development process, facilitating the regulatory approval of new therapies. Government initiatives, such as expedited review processes and fast-track designations, help streamline the approval process for promising breast cancer drugs, allowing quicker access to innovative treatments for patients and stimulating market growth. Governments invest in healthcare infrastructure and support initiatives to improve access to breast cancer care. This includes the establishment of comprehensive cancer centers, the expansion of screening and diagnostic services, and the enhancement of treatment facilities. Government support ensures that patients have timely access to high-quality healthcare services, including the latest advancements in breast cancer therapeutics. Improved infrastructure and access to care contribute to market growth by increasing the demand for and utilization of breast cancer treatments. Governments initiate public awareness and education campaigns to promote breast cancer screening, early detection, and treatment options. These campaigns aim to raise awareness about the importance of early diagnosis, encourage regular screenings, and educate the public about found at treatment modalities. By promoting breast cancer awareness and education, governments help in early detection, leading to timely interventions and improved treatment outcomes. Increased awareness and education contribute to the growth of the market as more individuals seek medical attention and engage in breast cancer care.
Recent Development
- Enhertu is an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo. It received approval from Health Canada in November 2020. Enhertu is indicated for the treatment of HER2-positive, unresectable or metastatic breast cancer in patients who have received prior treatment with trastuzumab and a taxane. It combines the HER2-targeting properties of trastuzumab with a cytotoxic payload to deliver a more potent treatment option.
- Trodelvy is an antibody-drug conjugate developed by Immunomedics that received approval from Health Canada in December 2020. It is indicated for the treatment of metastatic triple-negative breast cancer (mTNBC) in patients who have received at least two prior therapies for metastatic disease. Trodelvy combines an anti-Trop-2 antibody with a cytotoxic payload, allowing targeted delivery of chemotherapy to cancer cells.
Market Segmentation
The Canada Breast Cancer Diagnostics Market can be segmented by type, product, application, end use, region, and competitive landscape. In terms of type, the market is segmented into imaging, biopsy, genomic tests, blood tests, and others. The product segment comprises platform-based products and instrument-based products. Applications of breast cancer diagnostics in Canada include screening, diagnostic and predictive, prognostic, and research. The end use sectors encompass hospitals & clinics, diagnostic centers and medical laboratories, and others.
Market Players
Philips Canada Ltd, Danaher Corp, Hologic Inc, Becton Dickinson Canada Inc, Thermo Fisher Scientific Inc, Genomic Health Inc, Argon Medical Devices Inc, Hoffmann-La Roche Ltd are some of the leading players operating in the Canada Breast Cancer Diagnostics Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Type By Product By Application By End Use By Region |
| Regional scope | Ontario; Quebec; Alberta; British Columbia; Saskatchewan and Manitoba; Rest of Canada |
| Key companies profiled | Philips Canada Ltd, Danaher Corp, Hologic Inc, Becton Dickinson Canada Inc, Thermo Fisher Scientific Inc, Genomic Health Inc, Argon Medical Devices Inc, Hoffmann-La Roche Ltd |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy